Search Results
Aug 31, 2026, 10:15 ET Oligonucleotide CDMO Market worth $11.14 billion by 2031 - Exclusive Report by MarketsandMarkets™
driven by portfolio expansion into advanced solid-phase synthesis and high-throughput purification lines. Additionally, growing demand for genetic and RNA-based therapies in clinical trials, for rare genetic disorders, and in oncology serves as a key investment area. Investment activity is increasingly
More news about: MarketsandMarkets
Aug 31, 2026, 08:45 ET NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
is designed to target several key mechanisms that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation, with the potential to inhibit disease progression.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative
More news about: NeuroSense
Aug 31, 2026, 08:05 ET TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
Aug. 31, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a peer-reviewed article in Cancers titled,
More news about: TransCode Therapeutics, Inc.
Aug 28, 2026, 07:00 ET CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene
Combines CREATE's multi-immune programming and RNA gene-writing platforms with WestGene's targeted LNP technology to support broad clinical proof of concept, including in China.Advances three next-generation in vivo CAR programs: dual-target CD19 × BCMA for autoimmune
More news about: CREATE Medicines, Inc.
Aug 27, 2026, 16:01 ET Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
exhausted cells or replacing them with new ones. Instead, the existing cells appear to be regaining function. Blood-based simultaneous multi-modal protein, RNA and plasma profiling supported this finding, demonstrating increases in immune cell populations associated with anti-tumor activity, reductions in markers
More news about: Kazia Therapeutics Limited
Aug 26, 2026, 09:00 ET ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation for RTX-117 in Charcot-Marie-Tooth Disease
neurology, immunology and inflammation, and oncology. Founded in 2021 by leaders in computational biology, RNA biology, genomics and drug discovery, ReviR integrates artificial intelligence with RNA biology to create disease-modifying therapies designed to be highly specific, effective and safe. ReviR's
More news about: ReviR Therapeutics
Aug 26, 2026, 07:00 ET Insmed to Present at September 2026 Investor Conferences
Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.Headquartered in Bridgewater, New Jersey, Insmed has offices and
More news about: Insmed Incorporated
Aug 25, 2026, 10:15 ET Peptide Synthesis Market worth $1.54 billion by 2031 - Exclusive Report by MarketsandMarkets™
Oligonucleotide Synthesis Market by Offerings (Synthesis products [Consumables, Equipment], Synthesized Oligos (Type [DNA, RNA], Oligo-based Drugs (Type [ASO, siRNA), Therapy Area [Rare Diseases, Neurology, Oncology], Competition - Global Forecast to 2031
More news about: MarketsandMarkets
Aug 25, 2026, 09:00 ET Lexogen Expands NGS Services with GCLP-Compliant Workflows
VIENNA, Aug. 25, 2026 /PRNewswire/ -- Lexogen, a specialist in RNA sequencing technologies and next-generation sequencing services, announces the availability of designated NGS service workflows operated in compliance
More news about: LEXOGEN
Aug 25, 2026, 09:00 ET Lexogen Expands NGS Services with GCLP-Compliant Workflows
VIENNA, Aug. 25, 2026 /PRNewswire/ -- Lexogen, a specialist in RNA sequencing technologies and next-generation sequencing services, announces the availability of designated NGS service workflows operated in compliance
More news about: LEXOGEN
Aug 25, 2026, 07:00 ET Basking Biosciences Announces Positive Topline Phase 1 Data for BB-025, the Reversal Agent for its Acute Ischemic Stroke Thrombolytic Therapy BB-031
rapid-acting reversal agent designed to specifically bind to and neutralize BB-031, Basking's lead candidate, within minutes. BB-031 is an investigational RNA aptamer designed to selectively inhibit von Willebrand Factor (vWF) and restore blood flow in patients with AIS. BB-025 is being developed to give clinicians
More news about: Basking Biosciences Inc.
Aug 24, 2026, 17:41 ET BreakBio, the Third Player in Personalized Drugs, Enters the Clinic
find better targets per patient. It is an AI first biotech company. For every patient, its platform integrates highest quality tumor DNA sequencing, RNA sequencing, mass-spectrometry-based immunopeptidomics (of that patient) with proprietary deep AI analysis to find better targets on that patient's cancer
More news about: BreakBio Corp.
Aug 24, 2026, 07:00 ET BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.Headquartered in Bridgewater, New Jersey, Insmed has offices and
More news about: Insmed Incorporated
Aug 23, 2026, 21:54 ET Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
Lilly Gateway Labs in San Diego represents a meaningful milestone for Rznomics' proprietary RNA platform," said Seong-Wook Lee, CEO of Rznomics. "We intend to advance the development and commercialization of our RNA therapeutics by active collaboration with the global biotech ecosystem."About Rznomics
More news about: Rznomics
Aug 20, 2026, 19:10 ET Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
This milestone represents the first clinical evaluation of an RNA-based therapeutic originating from Brii Bio's internal discovery efforts. While BRII-5395 is an mRNA therapeutic vaccine, the Company's broader RNA platforms encompass multiple RNA modalities. During the first half of 2026, Brii Bio progressed
More news about: Brii Biosciences Limited
Aug 20, 2026, 18:23 ET Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
with Nasdaq Listing Rule 5635(c)(4).About Atrium TherapeuticsAtrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food
More news about: Atrium Therapeutics
Aug 19, 2026, 15:30 ET Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases
Amplitude's taRNA approach is designed to separate the replicase and antigen-encoding RNA components, enabling flexible antigen design, formulation tuning, and dose optimization across vaccine programs. As compared to other RNA modalities, taRNA may enable enhanced potency, lower doses, and improved manufacturability."Our
More news about: Amplitude Therapeutics
Aug 19, 2026, 10:00 ET Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Announce Liquid Biopsy Screening Collaboration in Lung Cancer
period.Pillar's oncoReveal® Essential+ assay has been validated at LSI Medience for use as a screening test for circulating cell-free DNA (cfDNA) and cell-free RNA (cfRNA) samples collected from patients with lung cancer participating in the LC-SCRUM-Asia project. Testing will be performed by LSI Medience to support
More news about: Pillar Biosciences, Inc.
Aug 18, 2026, 09:30 ET Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Aug 18, 2026, 08:53 ET Pusan National University Researchers Uncover How Chronic Environmental Stress Drives Immune Dysfunction in Cold Tumors
Transduction and Targeted Therapy on June 5, 2026.To uncover this mechanism, the researchers combined bulk transcriptomic analyses, single-cell RNA sequencing, clinical patient cohort analyses, NK-cell functional assays, mouse tumor models, and clinical patient samples. They also investigated the
More news about: Pusan National University
Aug 17, 2026, 08:39 ET Dongguk University Researchers Develop Innovative Electromagnetically Controllable Gene Switch
Cell on May 28, 2026.To identify EMF-responsive genes, the researchers performed single-cell RNA sequencing (scRNA-seq) on mouse brain tissue following exposure to an EMF of 2.0 millitesla at 60 hertz. the team found exclusive upregulation of Lgr4 expression.
More news about: Dongguk University
Aug 17, 2026, 08:04 ET First Ascent Biomedical Names Dr. Gilberto Lopes Chairman of Its Medical Advisory Board
therapies to observe how an individual patient's cancer responds. The platform then integrates those functional drug-response results with genomic DNA and RNA information and machine-learning-guided analysis to identify tumor vulnerabilities and prioritize potential treatment options for consideration by the
More news about: First Ascent Biomedical
Aug 14, 2026, 11:00 ET Cells use a little-known molecule to protect themselves from iron overload
polyamine levels within neurons.The Jain Lab studies RNA, the intermediary between DNA and the tiny molecular machines called proteins that perform most of the essential tasks inside cells. The lab is particularly interested in how RNA folds, misfolds, and sometimes clumps inside cells.Jain
More news about: Whitehead Institute
Aug 13, 2026, 18:16 ET Innorna für den „Prix Galien USA Best Startup Award" 2026 nominiert
Massachusetts, 14. August 2026 /PRNewswire/ -- Innorna, ein Biotech-Unternehmen im klinischen Stadium, das RNA-Medikamente entwickelt, gab heute bekannt, dass es für den 2026 Prix Galien USA Best Startup Award nominiert wurde.
More news about: Innorna Co., Ltd.
Aug 13, 2026, 16:44 ET Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second
More news about: Atrium Therapeutics